<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00922896</url>
  </required_header>
  <id_info>
    <org_study_id>Gyeongsang-001</org_study_id>
    <nct_id>NCT00922896</nct_id>
  </id_info>
  <brief_title>Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Phase II Trial of Erlotinib in Combination With Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dong-A University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gyeongsang National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the response rate of gemcitabine, cisplatin and
      erlotinib in metastatic pancreatic cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the response rate associated with gemcitabine, erlotinib and cisplatin in patients with advanced pancreatic cancer</measure>
    <time_frame>Clinically assessed every cycle (month) and radiologically assessed every 2 cycles (6 weeks) with CT scan</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>GPE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine-Cisplatin-Erlotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine, Cisplatin, Erlotinib (Tarceva)</intervention_name>
    <description>Erlotinib 100 mg po q d daily AND
Gemcitabine 1000 mg/mÂ² with 250 mL of normal saline intravenously infusion over 30 mins on Day 1, 8
Cisplatin 25 mg/m2 with 150 mL of normal saline intravenously infusion over 60 mins on D1,8
Every 3 weeks</description>
    <arm_group_label>GPE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age older than 18

          -  Younger than 75

          -  ECOG performance status 0 or 1

          -  Histologically confirmed adenocarcinoma of the pancreas

          -  Metastatic pancreatic cancer

          -  No prior chemotherapy for metastatic pancreatic cancer

          -  A patient with at least one measurable primary lesion of which the diameter is
             confirmed to be 10mm in Spiral CT or multidetector CT (MD CT)

        Exclusion Criteria:

          -  A patient with no measurable disease

          -  A patient who received previous palliative chemotherapy for pancreatic cancer

          -  A patient with locally advanced pancreatic cancer

          -  A patient who received adjuvant chemotherapy for pancreatic cancer within 1 year

          -  A patient with previous active or passive immunotherapy

          -  A pregnant or lactating patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gyeongsang Unversity Hospital</name>
      <address>
        <city>JinJU</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2009</study_first_submitted>
  <study_first_submitted_qc>June 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2009</study_first_posted>
  <last_update_submitted>November 18, 2012</last_update_submitted>
  <last_update_submitted_qc>November 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gyeongsang National University Hospital</investigator_affiliation>
    <investigator_full_name>Jung Hun Kang</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Gemcitabine</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Erlotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

